GBP4 exhibits a split personality—favoring survival in ovarian cancer by supporting immune responses through immunomodulatory factors, yet worsening renal cancer outcomes by enhancing tumor resilience, echoing GBP1’s duality [28]. Here, GBP4 is linked to neoplasm.